Assessment of Physician and Patient Attitudes Toward Direct-to-Consumer (DTC) Promotion of Prescription Drugs

Forms and Documents

Document	Type	Status	Availability

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

IC ID	Collection	Type	Status	Form
6179	Assessment of Physician and Patient Attitudes Toward Direct-to-Consumer (DTC) Promotion of Prescription Drugs		Migrated

ICR Details

OMB Control No: 0910-0479	ICR Reference No: 200110-0910-001
Status: Historical Active	Previous ICR Reference No:
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Assessment of Physician and Patient Attitudes Toward Direct-to-Consumer (DTC) Promotion of Prescription Drugs
Type of Information Collection: New collection (Request for a new OMB Control Number)	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 12/04/2001
	Date Received in OIRA: 10/04/2001
Terms of Clearance: Approved consistent with changes described in FDA memos of 11-21- 01, 11-28-01 and 12-3-01. FDA shall conduct a study of nonres- pondents to the patient survey to assess the representativeness of the sample in this survey. Approval is for 18 months which will give FDA sufficient time to complete this collection.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	06/30/2003	06/30/2003
Responses	1	0	0
Time Burden (Hours)	637	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: The FDA is required under Food, Drug, and Cosmetic Drug, and Cosmetic Act to assure that the advertising of prescription drugs is truthful and not misleading. Under a final August 1999 guidance, manufacturers were instructed how to construct television and radio ads that were consistent with the regulations by disclosing both the benefits and the major risks of the prescription drug being advertised. At the time, FDA stated it would assess the effects of the guidance, and of the agency's DTC policies in general, within the subsequent two years. A number of DTC promotion increase the studies,........

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Assessment of Physician and Patient Attitudes Toward Direct-to-Consumer (DTC) Promotion of Prescription Drugs

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	1	0	0	1	0	0
Annual Time Burden (Hours)	637	0	0	637	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 10/04/2001

---